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Abstract
Background: Overcrowding and prolonged length of stay in emergency departments (ED) are increasing problems in hospitals. Rapid availability of 
all laboratory results has an impact on clinical decision-making, admissions or discharge decisions and resource utilisation. Increasing number of our 
urinary drugs of abuse (DOA) screens had a turnaround time (TAT) of up to 33 days after the discharge of the patient.
Materials and methods: Following an audit and a consultation period with clinicians using the service, a policy change was implemented to re-
duce the use of gas chromatography mass spectroscopy (GCMS): all requests would have a standard immunoassay (IA) test panel undertaken unless 
specifically they requested GCMS (including medico-legal) analysis.
Results: Almost all of the clinicians interviewed had no understanding of the DOA screening or the difference in the information generated between 
a confirmatory GCMS urine toxicology screen and IA DOA panel. It appeared none of the patients surveyed in the audit would have had a different 
clinical decision made if a GCMS had not been undertaken. Post change audit showed only 4.3% of drug requests for IA also received a confirmatory 
GCMS testing. The estimated saving post change implementation was $127,000 (AU $) in test costs alone over a two year period. The TAT of GCMS 
results was reduced to 3-4 days.
Conclusion: A laboratory-led behavioural change in test requesting is possible and sustainable provided the reason is clinically sound and accompa-
nied by consultation and availability of advice by phone when requested on test requesting or interpretation.
Key words: immunoassay; gas-chromatography mass spectrometry; pathology requests; drugs of abuse; urine testing; behavioural change; turna-
round time
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Overcrowding and prolonged length of stay (LOS) 
in emergency departments (ED) are an increasing 
problem in public hospitals (1). EDs and their pay-
ers (Governments or private providers) are under 
pressure to reduce LOS, improve health outcomes, 
and reduce costs. Although the operations of 
emergency services are complex, the availability 
of ancillary services, including clinically appropri-
ate turnaround time (TAT) for laboratory tests, in-
fluences patient care decisions. For example, a 60 
minute collection to validation TAT for general 
chemistry (electrolytes, liver function tests, and 
troponin) is the generally agreed acceptable TAT 
by laboratories for EDs and other critical care units 
(2,3).
Although there are many variables contributing to 
the increasing number of admissions to EDs, pres-
entations from drug overdoses; either intentional 
or accidental (prescription, non-prescription or il-
licit substances) are increasing due to the wide 
availability of drugs of abuse (DOA) and the fre-
quently changing armamentarium of natural, syn-
thetic and recreational drugs. To aid clinicians in 
diagnosis and management, urinary drug screens 
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(UDS) are widely used. Ideally, DOA results should 
be available at the same time as chemistry results 
for best patient care decisions. This is because rap-
id availability of all these results has an impact on 
multiple outcomes including clinical decision-
making, admissions or discharge decisions and re-
source utilisation.
Generally UDS are performed in cases where the 
patient has or is reported to have a history of in-
gestion, presents with specific symptoms or has 
experienced trauma (4). In our organization, we 
became aware of an increasing number of gas 
chromatography/mass spectrometry (GCMS) drug 
screens being undertaken. Additionally, in some 
instances, our GCMS turnaround time had blown 
out up to 33 days, many weeks after the discharge 
of the patient. It was thus unclear how much ben-
efit our drug screening process was improving pa-
tient care. We hypothesized that there was over-
servicing of urine tests for drugs of abuse testing, 
causing the organization unnecessary cost with-
out clear and timely clinical benefit.
The aim was to assess the need for routine GCMS 
in screening for drugs of abuse in a tertiary referral 
centre.
Materials and methods
Medical facilities, patient types and testing 
processes in place
Our organisation (Pathology Queensland) oper-
ates 33 pathology laboratories with nine of these 
serving as major hospital service providers. Sam-
ples for DOA screening are received via EDs, inpa-
tient medical units, psychiatric units and various 
drug dependency/rehabilitation clinics. The nine 
major laboratories provide an immunoassay DOA 
panel on the general chemistry analysers (Beck-
man Coulter Brea, CA, USA). This consists of am-
phetamine like substances, benzodiazepines, can-
nabis metabolites, cocaine metabolites, metha-
done and opiates. Additionally, a confirmatory 
chromatography screening service to examine an 
extended array of drugs is offered (GCMS). The 
GCMS services provided are only qualitative which 
is used to confirm DOAs IA positives (and nega-
tives) by identification of specific drugs and their 
metabolites, as well as to provide a toxicology 
service for general drug enquiries. Some of the 
limitations are that services cannot routinely de-
tect and identify large molecular weight, highly 
polar and thermally labile drugs. The range of 
drugs able to be detected can be extended by 
chemical derivatisation, however this is not rou-
tinely performed. Overall, it detects many hun-
dreds of prescription and over-the-counter drugs 
as well as certain poisons (e.g. hyoscine and hyo-
scamine from datura, strychnine, caffeine and nic-
otine in infants, for example). Clinicians could or-
der either panel (rather than an initial screen) and 
a confirmatory GCMS test, regardless of the results 
of the IA test.
An audit undertaken pre-change (unpublished 
data) showed that 39.1% of drug requests for IA 
were also receiving a confirmatory GCMS test, re-
gardless of whether it had been requested. This 
audit was undertaken via a standard “extended” 
search of our laboratory information system to ex-
tract the patient samples undergoing IA DOA and 
GCMS testing. Where both were undertaken, the 
pathology request form was reviewed to check if 
GCMS had been requested. The cause of the addi-
tional requesting in the laboratory was not ana-
lysed.
Service impact
The ease with which a full GCMS screen was avail-
able was overwhelming the chromatography unit 
performing the analysis, affecting TAT in some cas-
es taking up to 33 days. The increasing workload, 
laboratory resource consumption and clinician de-
mand for better TAT of results began to have a sig-
nificant effect on the morale in our laboratory staff. 
When the audit results became available, a con-
sultative process was undertaken to determine 
why GCMS was requested so frequently as a front-
line panel, and what could be done to implement 
a change and improve service.
Consultative process
The process commenced by consultation with cli-
nicians and clinical units most frequently ordering 
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GCMS. The questions in the consultation process 
were:
Why chromatography?•	
Has an IA been performed?•	
If IA completed, what additional information •	
was hoped to be gained from chromatogra-
phy?
When was the data required?•	
Will the results change medical management?•	
It was noted that almost all of the twenty clinicians 
(junior medical staff) interviewed had no under-
standing of the DOA screening and the difference 
in the information generated between GCMS and 
IA. At one large urban Drug and Alcohol Clinic it 
appeared that none of the medical attendees had 
a working knowledge of the laboratory tests be-
ing requested, but this was not formally assessed.
A decision was made to issue a directive Pathology 
Queensland wide that all requests for drugs of 
abuse testing would have a standard IA test un-
dertaken, unless there was a specific request on 
the pathology form for GCMS, or the samples were 
from neonates or for juvenile drug testing. Sam-
ples would not be routinely tested with GCMS; 
however, the samples were to be held for 7 days 
so that a clinician could request a GCMS should it 
be required retrospectively.
Specimens for medico-legal or forensic needs 
were required to be packaged in line with chain-
of-custody guidelines and forwarded to a forensic 
toxicology laboratory. Additionally, guidelines for 
DOA and toxicology investigations were devel-
oped and appended with all results to inform clini-
cians of the change and the new procedures. Fur-
thermore, these most frequently requesting clini-
cians and units were directly verbally informed 
and then informed in writing of the change. This 
allowed clinicians to determine and specify on the 
request form if they had a need to look for addi-
tional and specific drugs e.g. newer “street” drugs, 
patient compliance for a single drug, for example.
Testing effectiveness
For the chromatography unit to improve TAT and 
for results to have greater clinical relevance when 
patients are in most need (overdose), it had to im-
prove TAT. This was something that could not be 
easily accommodated, without a new policy. Fur-
ther, there were concerns regarding any clinical or 
legal sequelae (e.g. for patients taking drugs of 
abuse whilst on an opioid maintenance pro-
gramme) if an IA drug screen was undertaken as 
the initial test, and GCMS was not routinely per-
formed. Since GCMS could still be undertaken as 
initial test if the requesting doctor informed the 
laboratory of the relevance of that test, effective-
ness was measured as in two ways - one was the 
number of either complaints or calls to the Pathol-
ogist hotline querying why an IA and not a GCMS 
test was undertaken; and the second was phone 
calls to the 20 most common ‘users’ of GCMS as an 
initial tool asking for clinical outcomes and feed-
back on the new policy.
Results
Consultative process
A total of 819 GCMS samples were audited and the 
10 most frequently requesting doctors and clinical 
units were consulted. These were mostly drug de-
pendency clinics and some ED and Mental Health 
units. Their main reason for requesting GCMS was 
that immunoassays (IAs) were not as sensitive, es-
pecially at low concentrations (which although not 
having a clinical effect on the patient could indi-
cate diversion with medico-legal implications). 
There were other reasons less commonly cited in-
cluding cross-reactivity, medical reasons e.g. pa-
tient stopping therapies, the need for knowledge 
of presence of buprenorphine or medico-legal 
tests. Pathology Queensland agreed that where 
there was one of these indications, GCMS would 
be undertaken.
Numbers of requests and pattern analysis
The five yearly sample numbers pre and post-test 
ordering protocol change for IA and GCMS are 
shown in Table 1.
A subset of samples in each 3-month period of IA 
and GCMS testing results were examined before 
the change and after the change. Further, GCMS 
requests were compared with IA results to exam-
ine false negative and false positive results. Pathol-
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IA – immunoassay; GCMS - gas chromatography mass spectroscopy
Table 1. Number of samples over time period: pre and post-test ordering protocol change. Change in ordering practice was in the 
mid March, Year Three.
ogy request forms were examined for clinical indi-
cation. It should be noted that there was a much 
higher proportion of IA drugs confirmed on GCMS 
in the post change set for amphetamines (pre 
70.1%, post 76.4%) and methadone (pre 92.7%, 
post 97.5%) and lower proportion for benzodi-
azepines (pre 89.6%, post 78.9%), and opiates (pre 
94.4%, post 90.4%) compared to the pre change 
set. The data suggested there was minimal differ-
ence in detecting the presence of the selected 
drugs between IA as GCMS methodologies even 
though GCMS analysis post positive IA would only 
be undertaken if there was a requested clinical in-
dication. Audit of the post change set requests 
showed only 4.3% of drug requests for IA were 
also receiving confirmatory GCMS testing, com-
pared to 39% prior to intervention.
Drugs that were not detected by IA but confirmed 
by GCMS were likely to be due to drugs present 
below the set cut-off limits for the IA, as specified 
by Pathology Queensland and based on the AS/
NZS 4308:2008 standard (Australian and New Zea-
land Standard providing cut off limits for drugs). 
The drugs detected by IA but not confirmed by 
GCMS are likely to be due to cross-reactivity of the 
immunoassay methods, resulting in false positive 
results (5). Although some of the drugs not con-
firmed by GCMS have been tested up to defined 
concentrations by Beckman (Beckman Coulter, 
Brea, CA USA), they (or their metabolites) may 
cross-react above these concentrations sufficiently 
to produce a detectable value.
The mean TAT (registered to validated) of results 
from two of our hospitals was also audited. From 
our second largest hospital, Princess Alexandra 
Hospital (PAH), and our most distant hospital 
(~1800 km), Cairns Base Hospital (CBH) which serv-
ices distant and dispersed remote communities, 
and small towns that may take days to send the 
samples to the laboratory. The audit data for PAH 
samples showed the TAT was 3-4 days for GCMS 
and < 70 minutes for IA results. The audit data for 
CBH which includes samples from the remote sites 
was 3-4 days for GCMS and ~13 hours for IA results, 
but samples originating from the CBH hospital had 
similar TATs, < 70 minutes.
Clinical outcome
Whilst it was suggested that not routinely under-
taking GCMS could lead to a reduction in patient 
care, analysis of the results show this was not 
borne out, bearing in mind the limitations of the 
clinician review of this retrospectively collected 
data for this study. Post review change showed 
less than 1% (0.63% amphetamines, 0.8% benzodi-
azepines) with a negative IA had a positive GCMS 
for a drug of abuse. These are likely to be due to 
concentration too low to be detected on IA. 1.9% 
(methadone – predominantly methadone detect-
ed on GCMS), and 10% opiates (predominantly bu-
prenorphine) were not detected on IA yet detect-
ed on GCMS. It is known that buprenorphine is not 
detected on the particular IA used within Patholo-
gy Queensland and clinicians have been advised 
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to request a GCMS if this drug is suspected. How-
ever, of these patients, none would have had a 
change in their acute care prior to the GCMS being 
undertaken. Buprenorphine testing does not gen-
erally come into play with acute or ED patients. It is 
more applicable to ATODS clinics. Our results sug-
gested the IA methods provided the required in-
formation on the presence or absence of the drugs 
of most interest in almost all cases when compared 
with GCMS, allowing clinicians to utilize the data in 
unison with other pathology results and clinical in-
formation in real time to best manage patients. 
The commonest feedback from clinicians was in-
creased confidence in the IA results, which allowed 
speedier decisions on clinical management; im-
proved time management – specifically time re-
quired by medical staff in attempts to extract in-
formation on drug consumption from unwilling 
and incapable patients and relatives in the con-
sultative phase, leading to improvement in pro-
ductivity. The availability of the results in improved 
TAT thus provides confidence in decision making, 
more in line with evidence based practices.
Cost savings
In the two years prior to the change, ~39% of IA 
samples had a GCMS screen. In contrast post 
change ~4% of samples had a GCMS screen. The 
cost to the clinical units of the 44,471 sample num-
bers requested for IA DOA in year 4 and 5 was 
~$1.62 M (AU$) while the cost of the 1790 GCMS 
sample numbers was ~$80,000. If the pre change 
practice was continued, an additional 35% (15,565 
samples) analysed by IA DOA would have had 
GCMS performed, costing additional ~$127,000 
over the two years.
Furthermore to have continued with the existing 
service and improve it, an additional staff member 
(~$100,000/year) and an additional GCMS system 
(~$1400,000) would have been required.
Discussion
In this study we have shown that changes in be-
haviour around test requests were possible with-
out obvious clinical harm. Despite the limitations 
of the methodology to retrospectively adjudicate 
clinical decision making, there were other clinical 
benefits reported due to the provision of improved 
TATs - necessary to make timely clinical decisions. 
A TAT over a month is a clinically irrelevant result, 
unless the test is required for medico legal reasons 
or concerns regarding specific drugs that would 
be unlikely to be detected with an IA (for which it 
was still possible to request a GCMS). The other 
gain was a large financial saving for our organiza-
tion, which could then be directed towards other 
needs. Specifically, the practice change has freed 
up two scientists to undertake other clinical work.
This laboratory-led change has been sustained – 
with changes persisting up to three years later. It is 
interesting that apart from phone advice when cli-
nicians rang pathology; there was no ongoing for-
mal education process around test requesting or 
interpretation.
This study is important for two reasons. Firstly, it 
shows that behavioural change and improved pa-
thology turnaround time is possible. Secondly, it 
demonstrates how improved efficiency of labora-
tory processes can improve costs significantly, 
both directly and indirectly via improved patient 
TAT. In other studies it has been shown that labo-
ratory services may make up 5% of a hospital’s 
budget but facilitate 60-70% of all critical decision-
making such as admittance, discharge, and medi-
cation (6). More recent publications estimate this 
to be as high as 80-90% (7). Approximately 80% of 
complaints laboratories receive are about TAT, 
even though there are differences amongst clini-
cians on what constitutes acceptable TAT (8). It is 
estimated that 87% of dissatisfaction complaints 
originate from EDs, the place where most DOA 
testing is undertaken (9). These key points make 
laboratories pivotal in introducing change in test 
ordering patterns and behaviour. Laboratories 
know the intricate details of their costs (labour, 
equipment, reagents, performance, etc.), TATs, test 
details and have a high level of knowledge on the 
relevance of tests for patient care. Laboratories can 
guide the multidisciplinary team on efficient and 
effective utilization of their services. However, lab-
oratories are often reluctant to impose decision on 
clinical experts. This work has shown that it is pos-
sible to lead a change from Pathology and that is 
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sustainable on long-term basis. It is becoming 
more and more important that healthcare teams 
look for novel ways to provide timely, cost effec-
tive, and clinically applicable services so that clini-
cians are able to make evidence based patient care 
decisions. Thus, interventions like in this study are 
necessary and pathology services will need to be 
proactive drivers.
Drug-testing is perceived to have a low impact on 
therapy if not provided in good TAT. In fact, most 
poisoned patients are managed symptomatically 
and supportively regardless of the drug or poison’s 
identity (10) with timely urine DOA testing useful if 
antidote or specific therapeutic intervention is 
available, such as naloxone for opiates (4). Fabbri et 
al. similarly concluded that the use of multidrug 
analysis is questionable in the management of pa-
tients with acute drug poisoning, although it is 
rather useful to reassure the clinician of their ac-
tions (11). Other publications advocate such tests 
are not necessary as the clinical course of patients 
with suspected drug overdose can be predicted 
during the first few hours of observation (12). In 
some patients, such as those with altered mental 
status, where the medical history may be unclear 
at the time of presentation to the ED, drugs of 
abuse tests do aid clinicians in diagnosis and man-
agement of drug-related complications (13).
Other pathology services have also tried to man-
age improvement in the TAT by introducing point-
of-care drugs of abuse testing. A recent example 
of this has shown a $132,951 ($US) increase in cost 
but a savings of 15.5 hours per day bed time (14). 
However, this result could be considered as cost 
shifting savings only (i.e. from laboratory to the 
clinical unit) unlike our study which is pure cost 
savings. Equally it needs to be pointed out that the 
laboratory is far better equipped at ensuring high-
est quality assurance is achieved with results. Per-
forming urine drug screens by IA methods on ex-
isting general biochemistry analysers provides a 
very rapid and cost effective mechanism. Howev-
er, as seen in this study, IA methods can produce 
false positive or negative results. Hence, the avail-
ability of confirmatory drug testing by chromato-
graphic methods where it is clinically necessary is 
still important. This decision however is different 
to the use of the GCMS for every urine drug sam-
ple screening.
Conclusion
The pathology initiated change for improving TAT 
of DOA testing has resulted in the provision of a 
rapid and relatively inexpensive service for most 
of the patients across our network to aid critical 
clinical care decisions. The change led to almost 
instantaneous change in test ordering behaviour 
by clinicians without leading to any obvious clini-
cal harm, to a very significant improvement in TAT 
and cost savings, immediately and then sustained.
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